Nothing Special   »   [go: up one dir, main page]

HUP0104702A2 - Klosztridium toxinszármazékok alkalmazása horkolási zajok elnyomására szolgáló gyógyászati készítmények előállítására - Google Patents

Klosztridium toxinszármazékok alkalmazása horkolási zajok elnyomására szolgáló gyógyászati készítmények előállítására

Info

Publication number
HUP0104702A2
HUP0104702A2 HU0104702A HUP0104702A HUP0104702A2 HU P0104702 A2 HUP0104702 A2 HU P0104702A2 HU 0104702 A HU0104702 A HU 0104702A HU P0104702 A HUP0104702 A HU P0104702A HU P0104702 A2 HUP0104702 A2 HU P0104702A2
Authority
HU
Hungary
Prior art keywords
bont
clostridial toxin
snoring
toxin
snoring noises
Prior art date
Application number
HU0104702A
Other languages
English (en)
Inventor
Hans Bigalke
Jürgen Frevert
Original Assignee
BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH filed Critical BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH
Publication of HUP0104702A2 publication Critical patent/HUP0104702A2/hu
Publication of HUP0104702A3 publication Critical patent/HUP0104702A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A tal lm ny nagy tisztas gú BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E,BoNT/F, BoNT/G és/vagy TeNT klosztridium toxin alkalmaz sa horkol sizajok elnyom s ra szolg ló, intramuszkul risan beadandó gyógy szatikészítmény elő llít s ra. A tal lm ny t rgyk"réhez tartozik tov bbBoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G és TeNTklosztridium toxin k"zül egyik klosztridium k"nnyű alegységét és egy msik klosztridium toxin nehéz alegységét tartalmazó hibrid protein(ek)alkalmaz sa klosztridium toxinként horkol si zajok elnyom s ra szolgló, intramuszkul risan beadandó gyógy szati készítmény elő llít s ra.A tal lm ny ezenkívül klosztridium toxint vagy hibrid proteint és egyvagy t"bb gyógy szatilag jól torel lt hemagglutinint és/vagy egy vagyt"bb gyógy szatilag jól toler lt nem toxikus proteint tartalmazókomplex alkalmaz sa horkol si zajok elnyom s ra szolg ló, intramuszkulrisan beadandó gyógy szati készítmény elő llít s ra. Ó
HU01047020104702A 1998-12-10 1999-12-10 Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises HUP0104702A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen
PCT/EP1999/009791 WO2000033863A2 (de) 1998-12-10 1999-12-10 Therapeutikum zur unterdrückung von schnarchgeräuschen

Publications (2)

Publication Number Publication Date
HUP0104702A2 true HUP0104702A2 (hu) 2002-04-29
HUP0104702A3 HUP0104702A3 (en) 2003-09-29

Family

ID=7890562

Family Applications (1)

Application Number Title Priority Date Filing Date
HU01047020104702A HUP0104702A3 (en) 1998-12-10 1999-12-10 Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises

Country Status (21)

Country Link
US (1) US6573241B1 (hu)
EP (1) EP1137430B1 (hu)
JP (1) JP4700811B2 (hu)
KR (1) KR100859556B1 (hu)
CN (1) CN1186095C (hu)
AT (1) ATE234108T1 (hu)
AU (1) AU764744B2 (hu)
BR (1) BR9915800A (hu)
CA (1) CA2353469A1 (hu)
CZ (1) CZ295769B6 (hu)
DE (2) DE19856897A1 (hu)
DK (1) DK1137430T3 (hu)
ES (1) ES2192880T3 (hu)
HK (1) HK1040636B (hu)
HU (1) HUP0104702A3 (hu)
IL (2) IL143528A0 (hu)
NO (1) NO328762B1 (hu)
PL (1) PL202908B1 (hu)
PT (1) PT1137430E (hu)
RU (1) RU2243783C2 (hu)
WO (1) WO2000033863A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
CA2611936C (en) * 2005-06-14 2017-01-03 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
AU2006346369B2 (en) 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
EP3295955B1 (en) 2005-12-01 2021-04-07 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
BRPI0719756A2 (pt) 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
EP2310000B1 (en) * 2008-06-26 2019-09-18 Anterios, Inc. Dermal delivery
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
EP2498810A4 (en) * 2009-11-09 2013-10-30 Ira Sanders TREATMENT OF RESPIRATORY DISORDERS OF SLEEP BY NEUROTOXIN
ES2708661T3 (es) 2011-05-19 2019-04-10 Ipsen Bioinnovation Ltd Métodos para la fabricación de polipéptidos proteolíticamente procesados
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) * 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP1072270B1 (en) * 1993-12-28 2005-10-19 Allergan, Inc. Botulinum toxin for treating dystonia
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9354569B2 (en) 2013-06-13 2016-05-31 Lexmark International, Inc. Heat transfer system for a fuser assembly

Also Published As

Publication number Publication date
NO328762B1 (no) 2010-05-10
ES2192880T3 (es) 2003-10-16
AU3037400A (en) 2000-06-26
EP1137430A2 (de) 2001-10-04
AU764744B2 (en) 2003-08-28
PL349334A1 (en) 2002-07-15
ATE234108T1 (de) 2003-03-15
PT1137430E (pt) 2003-07-31
IL143528A0 (en) 2002-04-21
CN1186095C (zh) 2005-01-26
DE59904569D1 (de) 2003-04-17
US6573241B1 (en) 2003-06-03
IL143528A (en) 2008-04-13
WO2000033863A2 (de) 2000-06-15
JP2002531516A (ja) 2002-09-24
HK1040636A1 (en) 2002-06-21
CZ20012058A3 (cs) 2001-09-12
DE19856897A1 (de) 2000-06-15
HK1040636B (zh) 2003-05-30
KR20010089527A (ko) 2001-10-06
KR100859556B1 (ko) 2008-09-22
BR9915800A (pt) 2001-09-25
HUP0104702A3 (en) 2003-09-29
EP1137430B1 (de) 2003-03-12
NO20012716L (no) 2001-06-01
WO2000033863A3 (de) 2000-11-02
PL202908B1 (pl) 2009-08-31
JP4700811B2 (ja) 2011-06-15
RU2243783C2 (ru) 2005-01-10
CZ295769B6 (cs) 2005-11-16
CN1329501A (zh) 2002-01-02
CA2353469A1 (en) 2000-06-15
NO20012716D0 (no) 2001-06-01
DK1137430T3 (da) 2003-06-16

Similar Documents

Publication Publication Date Title
HUP0104702A2 (hu) Klosztridium toxinszármazékok alkalmazása horkolási zajok elnyomására szolgáló gyógyászati készítmények előállítására
HUP0101831A2 (hu) Szulfonamidszármazékok mint aszpartil-proteáz inhibitorok prodrugjai és ezeket tartalmazó gyógyszerkészítmények
MY118371A (en) Tetrahydrolipstatin containing compositions
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
CA2293470A1 (en) Benzimidazole derivatives
BG101118A (en) Therapeutical compounds
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HUP9900887A2 (hu) A hipotalamuszra ható, új norpregnánszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
NO964413D0 (no) Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav
MX9501848A (es) Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
MX9708800A (es) Compuestos biciclicos aromaticos.
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
HUP0202803A2 (en) Titanium derived compounds, preparation and use thereof
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERZ PHARMA GMBH & CO. KGAA, DE

Free format text: FORMER OWNER(S): BIOTECON GESELLSCHAFT FUER BIOTECHNOLOGISCHE ENTWICKLUNG UND CONSULTING MBH, DE

FD9A Lapse of provisional protection due to non-payment of fees